2005 Fiscal Year Final Research Report Summary
The development of targeted therapies using FKHRL1 for the treatment of leukemia
| Project/Area Number |
15390306
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Hematology
|
|---|
| Research Institution | University of Yamanashi (2004-2005)
Jichi Medical University (2003) |
|---|
Principal Investigator |
KOMATSU Norio University of Yamanashi, University of Yamanashi Hospital, Professor, 医学部附属病院, 教授 (50186798)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KIRITO Keita University of Yamanashi, University of Yamanashi Hospital, Associate Professor, 医学部附属病院, 助教授 (90306150)
|
|---|
| Project Period (FY) |
2003 – 2005
|
| Keywords | FKHRL1 / FOXO3a / TRAIL / APL / apoptosis / drug-sensitivity / autocrine / all-trans retinoic acid |
|---|
| Research Abstract |
FKHRL1 (also called FOXO3a) is a member of the FOXO subfamily of Forkhead transcription factors and lies downstream of cytokine signaling pathways. This molecule is phosphorylated by activated Akt/Gsk and remains in the cytoplasm as an "inactive form". In this study, we found that FKHRL1 functions downstream of Bcr-Abl tyrosine kinase as a phosphorylated "inactive" form in chronic myelogenous leukemia (CML). The Bcr-Abl tyrosine kinase inhibitor imatinib induced cell cycle arrest and subsequent apoptosis via the conversion of FKHRL1 from the phosphorylated "inactive" form to the dephosphorylated "active" form in CML-derived cell lines. To examine whether "active" FKHRL1 can overcome the resistance to imatinib, we generated a 4-hydroxytamoxifen (4-OHT)-inducible "active" FKHRL1 (FKHRL1-TM ; a triple mutant of FKHRL1 in which all three Akt phosphorylation sites have been mutated)-estrogen receptor fusion protein expression system in CML-derived imatinib-resistant cell lines. 4-OHT inhibited the cell growth and cell cycle progression, and subsequently induced apoptosis, accompanied by up-regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Thus, "active" FKHRL1 antagonized deregulated proliferation and induced apoptosis in these cell lines.
Moreover, we also found that all-trans retinoic acid (ATRA) induced apoptosis via FKHRL1-mediated TRAIL production in APL-derived cell line NB4 which was sensitive to ATRA. Like CML cells, over-expression of "active" FKHRL1 induced apoptosis not only in ATRA-sensitive cell line NB4 but also in ATRA-resistant NB4R cell line. Therefore, our results suggest that "active" FKHRL1 can overcome imatinib resistance and ATRA resistance in CML and APL cell lines, respectively, in part via TRAIL production.
|
Research Products
(22 results)
